Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN NGUYEN

Allopathic & Osteopathic Physicians Ophthalmology Ophthalmic Plastic and Reconstructive Surgery

NPI
1457556003
CMS profile
65988
Location
MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$66,073.77

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $39,650.92 79
ANI Pharmaceuticals, Inc. $18,234.21 15
Kerecis Limited $7,633.50 14
BIOTISSUE HOLDINGS INC. $230.51 1
Organogenesis Inc. $185.95 2
Sight Sciences, Inc. $82.94 1
Alcon Vision LLC $29.66 1
Merz Pharmaceuticals, LLC $26.08 1

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN NGUYEN

NPI 1457556003 · CMS profile ID 65988

Allopathic & Osteopathic Physicians / Ophthalmology / Ophthalmic Plastic and Reconstructive Surgery

MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457556003?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN NGUYEN, NPI 1457556003, CMS profile ID 65988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457556003?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOHN NGUYEN, NPI 1457556003, CMS profile ID 65988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457556003?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOHN NGUYEN, NPI 1457556003, CMS profile ID 65988, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1457556003?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $66,073.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–114 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $33.7803/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228462847 CMS
Amgen Inc. $6.1503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227141012 CMS
Kerecis Limited $3,590.0002/18/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1243708136 CMS
Kerecis Limited $47.5602/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243714689 CMS
Kerecis Limited $397.9302/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1243714691 CMS
Organogenesis Inc. $35.9601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242029992 CMS
Kerecis Limited $84.5501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243679123 CMS
Kerecis Limited $277.9701/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1243679125 CMS
Amgen Inc. $3,150.0001/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226888539 CMS
Amgen Inc. $1,050.0001/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226888541 CMS
Amgen Inc. $34.2501/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228462837 CMS
Merz Pharmaceuticals, LLC $26.0801/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232561839 CMS
Amgen Inc. $730.0001/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226906889 CMS
Amgen Inc. $114.5101/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228462821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,799.45 12
PY2020 $3,089.46 2
PY2021 $6,186.81 5
PY2022 $13,031.63 15
PY2023 $31,517.99 38
PY2024 $39,993.60 59
PY2025 $66,073.77 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $255,610.16 28
PY2024 Principal investigator $284,297.47 3
PY2023 Principal investigator $2,000.00 1
PY2022 Principal investigator $5,063.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $3,029.86 12/11/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237157931
Principal investigator 1 ARGENX US, INC. $441.00 12/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162091
Principal investigator 1 ARGENX US, INC. $53.00 12/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162096
Principal investigator 1 ARGENX US, INC. $1,123.48 11/14/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237157934
Principal investigator 1 ARGENX US, INC. $53.00 11/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162100
Principal investigator 1 ARGENX US, INC. $441.00 11/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162109
Principal investigator 1 ARGENX US, INC. $6,054.36 10/23/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237157927
Principal investigator 1 ARGENX US, INC. $53.00 10/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162086
Principal investigator 1 ARGENX US, INC. $441.00 10/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162104
Principal investigator 1 Amgen Inc. $34,456.59 10/01/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA WEST VIR
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246648730
Principal investigator 1 ARGENX US, INC. $53.00 09/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162070
Principal investigator 1 ARGENX US, INC. $441.00 09/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162075
Principal investigator 1 ARGENX US, INC. $2,000.00 08/21/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237157938
Principal investigator 1 ARGENX US, INC. $15,975.00 08/21/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237157943
Principal investigator 1 ARGENX US, INC. $53.00 08/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162062
Principal investigator 1 ARGENX US, INC. $441.00 08/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162066
Principal investigator 1 ARGENX US, INC. $53.00 07/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162079
Principal investigator 1 ARGENX US, INC. $441.00 07/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162083
Principal investigator 1 ARGENX US, INC. $441.00 06/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162037
Principal investigator 1 ARGENX US, INC. $53.00 06/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162043
Principal investigator 1 Amgen Inc. $1,662.95 05/23/2025 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246652153
Principal investigator 1 ARGENX US, INC. $53.00 05/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162052
Principal investigator 1 ARGENX US, INC. $441.00 05/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162059
Principal investigator 1 ARGENX US, INC. $28.27 04/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162048
Principal investigator 1 ARGENX US, INC. $235.20 04/01/2025 Non-covered Recipient Entity
WVU Eye Institute
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237162054
Principal investigator 1 Amgen Inc. $20,169.45 04/01/2025 Non-covered Recipient Entity
STATE OF WEST VIRGINA WEST VIRGINIA UNIVERSITY
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246648732
Principal investigator 1 Amgen Inc. $151,062.00 03/04/2025 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246652181
Principal investigator 1 Genentech, Inc. $15,861.00 02/18/2025 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH
Subcutaneous anti IL6R for treatment of patients with Thyroid Eye Disease No dispute reported 06/30/2026 1211684992